New trial clinical trial is focused on novel therapy for triple negative breast cancer.
(SAN ANTONIO) April 14, 2022 –– When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer (TNBC) with an anti-drug conjugate used in monotherapy or in combination with antiPDL1.
Dr. Valentina Boni, a medical oncologist and principal investigator, is the clinical operations manager at NEXT-Madrid which is in the Hospital Universitario Quirónsalud Madrid. She says more combinations need to be explored to treat those patients who are resistant to antiPDL1 with metastatic disease or as early recurrence for patients treated with curative intent.
“We are thrilled to have our first patient already treated at NEXT-Madrid, and our goal is to have new trials with the latest compounds in development at our clinic,” Dr. Boni said. “This represents a clear opportunity for patients with cancer to have access to these new compounds, that are, at least theoretically, more effective and less toxic than standard therapies. We are convinced that clinical research is a good strategy for improving quality of life and survival of our cancer patients.”
NEXT Oncology’s phase I centers provide patients with advanced cancer whose cancer no longer responds to other treatment options access to the newest cancer treatments available. According to Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, the global expansion into Spain was another step in a series of planned collaborations to bring NEXT Oncology’s proprietary model of Phase I clinical trials to over 12 cities all over the U.S. as well as other parts of the world.
“Cancer has no geographic boundaries,” said Dr. Tolcher said. “One of the continuing challenges has been that cancer research has been conducted in silos. Our goal has always been to break down those barriers and bring potentially life-saving therapies to people around the world, while at the same time expediting the development of new therapies for the treatment and eventual cure of cancer. I believe we are going to make cancer treatable or curable in my lifetime.”
Headquartered in San Antonio, NEXT Oncology opened NEXT-Austin in July 2021 and entered a joint venture with Virginia Cancer Specialists in September to form NEXT-Virginia. In November, Dr. Tolcher opened NEXT-Barcelona and NEXT-Madrid. NEXT-Dallas is slated is slated to open later in 2022.
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with
Texas Oncology, the largest private oncology practice in the United States with more than 400 referring oncologists and US Oncology, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.